Artera Gains California Lab License to Offer Prostate Test
Artera, a leader in artificial intelligence (AI) for cancer diagnostics, recently announced the attainment of its official laboratory license from the California Department of Public Health (CDPH). This important step opens the door for Artera to provide its revolutionary ArteraAI Prostate Test across one of the largest healthcare markets in the United States.
Innovative Features of the ArteraAI Prostate Test
The ArteraAI Prostate Test stands out as the first diagnostic tool capable of both predicting therapy benefits and forecasting long-term outcomes for patients grappling with localized prostate cancer. Clinicians and patients in California will be able to access this cutting-edge test, equipped with data-driven insights to guide personalized cancer treatment strategies.
Significance of the License Acquisition
“This California lab license marks a significant achievement for Artera, enabling us to expand our reach to more patients and health professionals across the nation,” said Andre Esteva, the CEO and co-founder of Artera. Considering prostate cancer's prevalence in American men, with estimates indicating that over 26,000 men are anticipated to face a diagnosis within California annually, this advancement is particularly vital. “Our ambition is to streamline access to AI-driven precision medicine, granting patients clearer insights into their treatment pathways,” Esteva emphasized.
Quality Assurance and Accreditation
The newly acquired laboratory license comes on the heels of Artera's accreditation by the College of American Pathologists (CAP). This rigorous process involved comprehensive inspections aimed at evaluating laboratory staff qualifications, equipment quality, and overall management to uphold superior standards of patient care. Ultimately, these endorsements reflect Artera's unwavering commitment to safety and quality in laboratory practices.
Expert Opinions on the Test
Peter Carroll, MD, MPH, a distinguished Professor of Urology at the University of California, San Francisco, expressed enthusiasm regarding the accessibility of the ArteraAI Prostate Test in California. He noted, “The initial development of the MMAI biomarker was significantly influenced by research here at UCSF. The recognition of Artera’s predictive biomarker in national guidelines for localized prostate cancer stands to notably enhance treatment decisions—especially for patients contemplating androgen deprivation therapy (ADT) alongside radiation.”
He conveyed a powerful message emphasizing that both clinicians and patients are entitled to access innovative technologies that have been extensively validated, which will ensure that they receive the most personalized and optimal level of care.
About Artera and Its Pioneering Work
Artera is a trailblazer in the field of precision medicine, dedicated to developing AI-based tests tailored to personalize cancer therapies. The ArteraAI Prostate Test is unique, offering both prognostic and predictive information specifically for patients with localized prostate cancer.
The company's MMAI biomarker test employs a sophisticated algorithm that analyzes digital images obtained from patient biopsies alongside clinical data. This confluence of information allows the AI to effectively determine prognosis and predict whether patients could benefit from certain therapies. This innovative approach has been validated through numerous Phase 3 randomized trials.
Clinical Availability of the Test
The ArteraAI Prostate Test is currently available through Artera's CLIA-certified and CAP-accredited laboratory located in Jacksonville, Florida. Individuals looking to order this test can conveniently do so online via Artera's official website.
Frequently Asked Questions
What is the ArteraAI Prostate Test?
The ArteraAI Prostate Test is an innovative diagnostic tool that predicts therapy benefits and long-term outcomes for localized prostate cancer patients.
What significance does the California lab license hold for Artera?
This license enables Artera to provide its AI-powered prostate test to a wider base of patients and healthcare professionals in California.
How does the ArteraAI Prostate Test work?
The test utilizes a unique AI algorithm to analyze biopsy images and clinical data to give insights about a patient's cancer prognosis and potential therapy benefits.
What recognition has Artera received regarding quality assurance?
Artera has achieved accreditation from the College of American Pathologists (CAP), ensuring high standards for laboratory safety and quality.
Where can individuals access the ArteraAI Prostate Test?
The test is clinically available through Artera's laboratory in Jacksonville, Florida, with options for online ordering via Artera's website.
